Fix compounding sections of Senate proposal, NCPA's CEO says

SB 959 would restrict patient access to customized medications by authorizing FDA oversight of what small pharmacies can prepare or "compound" in response to a physician's request, writes National Community Pharmacists Association CEO B. Douglas Hoey in response to a July 31 editorial stating that the bill leaves oversight of such pharmacies to states. The bill would inhibit pharmacies' ability to compound drugs to fill the void left by shortages, he writes. Hoey suggests that the Senate pass the anti-drug counterfeiting provisions of the proposal to prevent meningitis outbreaks and similar tragedies, but delay passing the sections on drug compounding until they can be revised.

View Full Article in:

Washington Post (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC